scholarly journals Effects of Lactobacillus plantarum Q180 on Postprandial Lipid Levels and Intestinal Environment: A Double-Blind, Randomized, Placebo-Controlled, Parallel Trial

Nutrients ◽  
2020 ◽  
Vol 12 (1) ◽  
pp. 255 ◽  
Author(s):  
Ye Eun Park ◽  
Min Seo Kim ◽  
Kyung Won Shim ◽  
You-Il Kim ◽  
Jaeryang Chu ◽  
...  
Keyword(s):  
Lactobacillus Plantarum ◽  
Intestinal Microbiome ◽  
Controlled Study ◽  
Lipid Levels ◽  
Double Blind ◽  
Apo B ◽  
Intestinal Environment ◽  
Postprandial Lipid Metabolism ◽  
Postprandial Lipid ◽  
Underlying Mechanisms

Probiotics can improve the intestinal environment by enhancing beneficial bacteria to potentially regulate lipid levels; however, the underlying mechanisms remain unclear. The aim of this study was to investigate the effect of Lactobacillus plantarum Q180 (LPQ180) on postprandial lipid metabolism and the intestinal microbiome environment from a clinical perspective. A double-blind, randomized, placebo-controlled study was conducted including 70 participants of both sexes, 20 years of age and older, with healthy blood triacylglyceride (TG) levels below 200 mg/dL. Treatment with LPQ180 for 12 weeks significantly decreased LDL-cholesterol (p = 0.042) and apolipoprotein (Apo)B-100 (p = 0.003) levels, and decreased postprandial maximum concentrations (Cmax) and areas under the curve (AUC) of TG, chylomicron TG, ApoB-48, and ApoB-100. LPQ180 treatment significantly decreased total indole and phenol levels (p = 0.019). In addition, there was a negative correlation between baseline microbiota abundance and lipid marker change, which was negatively correlated with metabolites. This study suggests that LPQ180 might be developed as a functional ingredient to help maintain healthy postprandial lipid levels through modulating gut environment.

Effects of Consumption of Probiotic Powder Containing Lactobacillus Plantarum Dad-13 on Fecal Bacterial Population in School-Age Children in Indonesia

2019 ◽  
Vol 14 (1) ◽  
pp. 1-8 ◽  
Author(s):  
Banin Maghfirotin Marta ◽  
Utami Tyas ◽  
Cahyanto Muhammad Nur ◽  
Widada Jaka ◽  
Rahayu Endang Sutriswati
Keyword(s):  
Placebo Group ◽  
Gut Microbiota ◽  
Lactobacillus Plantarum ◽  
Coliform Bacteria ◽  
School Age Children ◽  
Controlled Study ◽  
School Age ◽  
Double Blind ◽  
Probiotic Group ◽  
E Coli

Consumption of probiotics is known to influence the gut microbiota. The aim of this study was to assess the effect of probiotic powder containing Lactobacillus plantarum Dad-13 on bacterial composition in the gut by examining fecal samples of school-age children in Yogyakarta, Indonesia. This is a randomized, double-blind, placebo-controlled study. A total of 40 healthy subjects were recruited for this study and were divided into two groups: placebo group and probiotic group. The placebo group consumed skim milk and the probiotic group consumed probiotic powder containing L. plantarum Dad-13 (2 × 109 CFU/g) for 65 days. The results showed that placebo intake had no significant effect on gut microbiota; however, probiotic caused a significant increase in L. plantarum and Lactobacillus population, while decreasing the population of E. coli and non-E. coli coliform bacteria by 55% and 75%, respectively and Bifidobacteria count did not change significantly. The study concluded that consumption of probiotic powder L. plantarum Dad-13 could increase propionic acid thereby decreasing the gut pH which has an effect on the microbial population.

scholarly journals Effect of a food supplement containing berberine, monacolin K, hydroxytyrosol and coenzyme Q10 on lipid levels: a randomized, double-blind, placebo controlled study

2017 ◽  
Vol Volume 11 ◽  
pp. 1585-1592 ◽  
Author(s):  
Sergio D'Addato ◽  
Luciana Scandiani ◽  
Giuliana Mombelli ◽  
Francesca Focanti ◽  
Federica Pelacchi ◽  
...  
Keyword(s):  
Coenzyme Q ◽  
Food Supplement ◽  
Controlled Study ◽  
Monacolin K ◽  
Lipid Levels ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Effects of Yeast Mannan Which Promotes Beneficial Bacteroides on the Intestinal Environment and Skin Condition: A Randomized, Double-Blind, Placebo-Controlled Study

Nutrients ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 3673
Author(s):  
Reiko Tanihiro ◽  
Katsuhisa Sakano ◽  
Shunsuke Oba ◽  
Chikako Nakamura ◽  
Kohji Ohki ◽  
...  
Keyword(s):  
Skin Condition ◽  
Water Soluble ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Intestinal Environment ◽  
Healthy Female ◽  
Soluble Polysaccharide ◽  
Bacteroides Ovatus

Yeast mannan (YM) is an indigestible water-soluble polysaccharide of the yeast cell wall. In vitro fecal fermentation studies showed that YM could exhibit a notable prebiotic effect. The aim of this randomized, double-blind, placebo-controlled study was to assess the efficacy of YM intake on the intestinal environment and skin condition. One hundred and ten healthy female subjects aged 30–49 years were supplemented with YM or placebo for eight weeks. Skin dryness was set as the primary endpoint. No side effects were observed during the study. Microbiota analyses revealed that YM intake selectively increased the relative abundance of Bacteroides thetaiotaomicron and Bacteroides ovatus compared to that by placebo. Feces and urine analyses showed that YM intake lowered the concentration of fecal p-cresol, indole, and skatole, and elevated urinal equol levels compared to those in placebo. Furthermore, YM supplementation ameliorated subjective skin dryness. This study suggests that YM intake could promote beneficial Bacteroides and improve the intestinal environment and skin condition.

Clinical Evidence of Effects of Lactobacillus plantarum HY7714 on Skin Aging: A Randomized, Double Blind, Placebo-Controlled Study

2015 ◽  
Vol 25 (12) ◽  
pp. 2160-2168 ◽  
Author(s):  
Dong Eun Lee ◽  
Chul-Sung Huh ◽  
Jehyeon Ra ◽  
Il-Dong Choi ◽  
Ji-Woong Jeong ◽  
...  
Keyword(s):  
Lactobacillus Plantarum ◽  
Clinical Evidence ◽  
Skin Aging ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo

Abstract 682: Lapaqistat Acetate Monotherapy: Effects of a Novel Squalene Synthase Inhibitor on LDL-C Levels and Other Lipid Parameters in Patients with Primary Hypercholesterolemia

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Harold E Bays ◽  
Robert J Weiss ◽  
James M Rhyne ◽  
Yinzhong Chen ◽  
Claudia Lopez ◽  
...  
Keyword(s):  
Study Drug ◽  
Squalene Synthase ◽  
Phase Iii ◽  
Lipid Lowering ◽  
Controlled Study ◽  
Lipid Lowering Therapy ◽  
Double Blind ◽  
Apo B ◽  
Primary Hypercholesterolemia ◽  
Hs Crp

Background: Lapaquistat acetate (LAPA) inhibits squalene synthase, an important enzyme in the cholesterol biosynthetic pathway. Early studies showed that LAPA reduced LDL-C and improved lipid profiles in animals and humans. Methods: This multicenter, phase III, randomized, double-blind, parallel-group, placebo-controlled study assessed LAPA monotherapy in nondiabetic patients ≥ 18 yrs old with primary hypercholesterolemia (mean LDL-C > 130 mg/dL and < 220 mg/dL; mean triglyceride [TG] ≤400 mg/dL). Treatment-naïve patients or patients discontinuing previous lipid-lowering therapy underwent a 6-wk dietary stabilization period, then were randomized to 100 mg LAPA (n = 241) or Placebo (n = 120) once daily for 12 wks. The primary endpoint was percent (%) change from baseline compared with Placebo in direct LDL-C at Wk 12 or last on-treatment value. Secondary endpoints included: % change in calculated LDL-C, non-HDL-C, total cholesterol (TC), Apo B, HDL-C, VLDL-C, Apo A1, TG, and hs-CRP. Safety was monitored using clinical and laboratory examinations. Results: LAPA significantly reduced LDL-C levels (see Table ) within 2– 4 wks of treatment initiation that were maintained throughout the study. LDL-C remained relatively unchanged in the Placebo group. Compared with Placebo, LAPA lowered LDL-C levels 20.09% by end of study (p < 0.001). Non-HDL-C, TC, Apo B, VLDL-C, Apo A1, TG, and hs-CRP were also significantly reduced vs Placebo. Both the overall adverse event (AE) profile and the rate of AEs considered potentially related to study drug (~24%), were similar between treatment groups. Two serious AEs occurred in each group; the 2 SAEs in lapaquistat-treated patients were considered not related to study drug. Conclusion: LAPA (100 mg/day) monotherapy provided significant improvements in LDL-C, non-HDL-C, TC, Apo B, VLDL-C, TG, and hs-CRP levels, was generally safe and well tolerated, and potentially represents a novel treatment for hypercholesterolemic patients.

Lactobacillus plantarum DR7 alleviates stress and anxiety in adults: a randomised, double-blind, placebo-controlled study

2019 ◽  
Vol 10 (4) ◽  
pp. 355-373 ◽  
Author(s):  
H.X. Chong ◽  
N.A. A. Yusoff ◽  
Y.-Y. Hor ◽  
L.-C. Lew ◽  
M.H. Jaafar ◽  
...  
Keyword(s):  
Lactobacillus Plantarum ◽  
Inflammatory Cytokines ◽  
Tryptophan Hydroxylase ◽  
Transforming Growth Factor ◽  
Human Study ◽  
Interleukin 10 ◽  
Plasma Cortisol Level ◽  
Controlled Study ◽  
Double Blind ◽  
Associate Learning

Probiotics have been reported to exert beneficial effects along the gut-brain axis. This randomised, double-blind and placebo-controlled human study aimed to evaluate such properties of Lactobacillus plantarum DR7 and its accompanying mechanisms in stressed adults. One hundred and eleven (n=111; DR7 n=56, placebo n=55) stressed adults were recruited based on moderate stress levels using the PSS-10 questionnaire. The consumption of DR7 (1×109 cfu/day) for 12 weeks reduced symptoms of stress (P=0.024), anxiety (P=0.001), and total psychological scores (P=0.022) as early as 8 weeks among stressed adults compared to the placebo group as assessed by the DASS-42 questionnaire. Plasma cortisol level was reduced among DR7 subjects as compared to the placebo, accompanied by reduced plasma pro-inflammatory cytokines, such as interferon-γ and transforming growth factor-α and increased plasma anti-inflammatory cytokines, such as interleukin 10 (P<0.05). DR7 better improved cognitive and memory functions in normal adults (>30 years old), such as basic attention, emotional cognition, and associate learning (P<0.05), as compared to the placebo and young adults (<30 years old). The administration of DR7 enhanced the serotonin pathway, as observed by lowered expressions of plasma dopamine β-hydroxylase (DBH), tyrosine hydroxylase (TH), indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase accompanied by increased expressions of tryptophan hydroxylase-2 and 5-hydroxytryptamine receptor-6, while stabilising the dopamine pathway as observed via stabilised expressions of TH and DBH over 12 weeks as compared to the placebo (P<0.05). Our results indicated that DR7 fulfil the requirement of a probiotic strain as per recommendation of FAO/WHO and could be applicable as a natural strategy to improve psychological functions, cognitive health and memory in stressed adults.

scholarly journals Successful Response to Microbiota-Based Drug RBX2660 in Patients with Recurrent Clostridium Difficile Infection is Associated with More Pronounced Alterations in Microbiome Profile

2017 ◽  
Vol 4 (suppl_1) ◽  
pp. S387-S387 ◽  
Author(s):  
Sahil Khanna ◽  
Ken Blount ◽  
Courtney Jones ◽  
Bill Shannon ◽  
Sharina Carter
Keyword(s):  
Placebo Group ◽  
Clostridium Difficile ◽  
Multinomial Distribution ◽  
Post Treatment ◽  
Intestinal Microbiome ◽  
Controlled Study ◽  
Sequencing Analysis ◽  
Dissimilarity Index ◽  
Double Blind ◽  
Stool Samples

Abstract Background Recurrent Clostridium difficile infections (rCDI) are associated with decreased diversity and altered intestinal microbiome compared with healthy patients. RBX2660, a standardized microbiota-based drug, is designed to restore microbiome diversity and composition in patients’. The effect of RBX2660 on rCDI patient microbiomes was evaluated by comparing pre- and post-treatment samples from PUNCH CD 2—a randomized, double-blind, placebo-controlled study. Methods rCDIsubjects were randomized to receive blinded treatments of 2 doses of RBX2660 (Group A), 2 doses of placebo (Group B), or 1 dose each of RBX2660 and placebo (Group C), by enema 7 days apart. Subjects submitted stool samples at baseline, day 7, 30, and 60 after treatment. Stool samples from responders to RBX2660 treatment per protocol defined as the absence of CDI for 8 weeks after treatment were compared with non-responders. Relative taxonomic abundances at the class level were determined using 16s rRNA sequencing analysis for 94 stool samples from 45 patients in Groups A and C. Relative abundance data were grouped longitudinally using Bray-Curtis dissimilarity index. Analyses were performed based on the Dirichlet-Multinomial distribution to compare group mean relative taxonomic abundances; Simpson and Shannon diversity indices were compared among groups longitudinally. Results Baseline patient microbiomes were similar across response groups. RBX2660 treatment shifted the relative microbiome densities with taxa-specific increase in Bacteroidia, Clostridia, and decrease in Gamma-proteobacteria abundance. A larger shift from baseline microbiome was seen in responders to RBX2600 compared with non-responders (Figure 1). Microbiome changes in responders were durable to 60 days. RBX2660 treatment increased Shannon and Simpson diversity at 7 days post-treatment in responders but not in non-responders (P &lt; 0.05). Conclusion RBX2660 treatment shifts patient intestinal microbiomes with greater alterations seen in those with a successful clinical outcome. Funded by Rebiotix Inc., Roseville, MN. Disclosures S. Khanna, Rebiotix, Inc.: Scientific Advisor, Consulting fee; K. Blount, Rebiotix, Inc.: Employee, Salary; C. Jones, Rebiotix, Inc.: Employee, Salary; B. Shannon, Rebiotix, Inc.: Research Contractor, Consulting fee; S. Carter, Rebiotix, Inc.: Research Contractor, Consulting fee

Sign in / Sign up

Export Citation Format

Share Document